PMID- 37599897 OWN - NLM STAT- MEDLINE DCOM- 20230908 LR - 20230917 IS - 1178-2005 (Electronic) IS - 1176-9106 (Print) IS - 1176-9106 (Linking) VI - 18 DP - 2023 TI - The Clinical Characteristics and Outcomes in Non-Frequent Exacerbation Patients with Chronic Obstructive Pulmonary Disease in the Chinese Population. PG - 1741-1751 LID - 10.2147/COPD.S417566 [doi] AB - BACKGROUND: We analyzed the clinical characteristics and outcomes in non-frequent exacerbation patients with chronic obstructive pulmonary disease (COPD). METHODS: In this retrospective cohort study, we enrolled patients with stable COPD from 12 hospitals. Non-frequent exacerbation was defined as less than two times of exacerbations in the past year. The non-frequent exacerbation patients were classified into less and more symptomatic groups based on the COPD Assessment Test (CAT) and modified Medical Research Council (mMRC). Finally, the non-frequent exacerbation patients with less and more symptomatic were classified into the long-acting muscarinic antagonist (LAMA), long-acting beta2-agonist (LABA)+inhaled corticosteroids (ICS), LABA+LAMA, and LABA+LAMA+ICS groups. Minimum clinically important difference (MCID) was defined as a CAT score decrease of >/= 2 during six months of follow-up. We recorded the number of exacerbations and mortality during one year of follow-up. RESULTS: A total of 834 (67.5%) non-frequent exacerbation patients with COPD were included in this study. The non-frequent exacerbation patients had a higher education level and body mass index (BMI), and lower CAT and mMRC scores (P<0.05). In addition, the non-frequent exacerbation patients had lower mortality and risk of future exacerbation, and were more likely to attain MCID (P<0.05). Furthermore, the non-frequent exacerbation patients with more symptomatic COPD treated with LABA+LAMA or LABA+LAMA+ICS were more likely to attain MCID and had a lower risk of future exacerbation (P<0.05). However, there were no significant differences among the different inhalation therapies in non-frequent exacerbation patients with less symptomatic COPD. CONCLUSION: The non-frequent exacerbation patients with COPD had a higher education level and BMI, a lower symptom burden, and better outcomes. In addition, LABA+LAMA should be recommended to non-frequent exacerbation patients with more symptomatic COPD, while mono-LAMA should be recommended to non-frequent exacerbation patients with less symptomatic COPD as the initial inhalation therapy. CI - (c) 2023 Liu et al. FAU - Liu, Dan AU - Liu D AD - Department of Respiratory and Critical Care Medicine, Changsha Hospital of Traditional Chinese Medicine (Changsha Eighth Hospital), Changsha, Hunan, 410000, People's Republic of China. FAU - Song, Qing AU - Song Q AD - Department of Respiratory and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, People's Republic of China. AD - Research Unit of Respiratory Disease, Central South University, Changsha, Hunan, 410011, People's Republic of China. AD - Diagnosis and Treatment Center of Respiratory Disease, Central South University, Changsha, Hunan, 410011, People's Republic of China. FAU - Zeng, Yuqin AU - Zeng Y AD - Department of Respiratory and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, People's Republic of China. AD - Research Unit of Respiratory Disease, Central South University, Changsha, Hunan, 410011, People's Republic of China. AD - Diagnosis and Treatment Center of Respiratory Disease, Central South University, Changsha, Hunan, 410011, People's Republic of China. FAU - Yi, Rong AU - Yi R AD - Department of Pulmonary and Critical Care Medicine, Zhuzhou Central Hospital, Zhuzhou, Hunan, 412000, People's Republic of China. FAU - Liu, Yi AU - Liu Y AD - Department of Pulmonary and Critical Care Medicine, Zhuzhou Central Hospital, Zhuzhou, Hunan, 412000, People's Republic of China. FAU - Li, Xin AU - Li X AUID- ORCID: 0000-0002-5471-5808 AD - Division 4 of Occupational Diseases, Hunan Prevention and Treatment Institute for Occupational Diseases, Changsha, Hunan, 412000, People's Republic of China. FAU - Chen, Yan AU - Chen Y AD - Department of Respiratory and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, People's Republic of China. AD - Research Unit of Respiratory Disease, Central South University, Changsha, Hunan, 410011, People's Republic of China. AD - Diagnosis and Treatment Center of Respiratory Disease, Central South University, Changsha, Hunan, 410011, People's Republic of China. FAU - Cai, Shan AU - Cai S AD - Department of Respiratory and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, People's Republic of China. AD - Research Unit of Respiratory Disease, Central South University, Changsha, Hunan, 410011, People's Republic of China. AD - Diagnosis and Treatment Center of Respiratory Disease, Central South University, Changsha, Hunan, 410011, People's Republic of China. FAU - Chen, Ping AU - Chen P AUID- ORCID: 0000-0001-6707-8636 AD - Department of Respiratory and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, People's Republic of China. AD - Research Unit of Respiratory Disease, Central South University, Changsha, Hunan, 410011, People's Republic of China. AD - Diagnosis and Treatment Center of Respiratory Disease, Central South University, Changsha, Hunan, 410011, People's Republic of China. LA - eng PT - Journal Article DEP - 20230815 PL - New Zealand TA - Int J Chron Obstruct Pulmon Dis JT - International journal of chronic obstructive pulmonary disease JID - 101273481 RN - 0 (Muscarinic Antagonists) SB - IM MH - Humans MH - Asian People MH - Body Mass Index MH - *East Asian People MH - Muscarinic Antagonists/adverse effects MH - *Pulmonary Disease, Chronic Obstructive/diagnosis/drug therapy MH - Retrospective Studies MH - Disease Progression PMC - PMC10439774 OTO - NOTNLM OT - chronic obstructive pulmonary disease OT - inhalation therapy OT - minimum clinically important difference OT - mortality OT - non-frequent exacerbation COIS- All authors have no conflicts of interest for this work. EDAT- 2023/08/21 06:42 MHDA- 2023/08/22 06:42 PMCR- 2023/08/15 CRDT- 2023/08/21 04:38 PHST- 2023/04/17 00:00 [received] PHST- 2023/07/24 00:00 [accepted] PHST- 2023/08/22 06:42 [medline] PHST- 2023/08/21 06:42 [pubmed] PHST- 2023/08/21 04:38 [entrez] PHST- 2023/08/15 00:00 [pmc-release] AID - 417566 [pii] AID - 10.2147/COPD.S417566 [doi] PST - epublish SO - Int J Chron Obstruct Pulmon Dis. 2023 Aug 15;18:1741-1751. doi: 10.2147/COPD.S417566. eCollection 2023.